WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) -- (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results